The HealthShares GI/Gender ETF (Ticker: HHU) seeks to replicate as closely as possible, before expenses, the total return performance of the HealthShares GI/Gender Index. The index is comprised of companies engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of diseases including, but not limited to, gastrointestinal disorders such as gastroesophageal reflux disease, heartburn, irritable bowel syndrome, Crohn's Disease and ulcerative colitis; genitourinary disorders such as overactive bladder, urge incontinence, stress incontinence and urinary tract infection; and gender health matters including sexual dysfunction (male and female), endometriosis, benign prostatic hyperplasia, prolapsed womb and reproductive health. Companies must have a minimum market capitalization greater than $100 million and less than $15 billion for at least two of the three proceeding quarters. Companies were equal weighted at the fund's inception, then allowed to float with the market thereafter. When the weight of an individual stock reaches 15% of the index value it is adjusted down to 10%, and when a stocks falls to 2.5% it is adjusted up to 5%. S&P is the administrator of HealthShares indexes.
